Covered recipient · General Payments record
MIHAELA C TEMPLER
Allopathic & Osteopathic Physicians Family Medicine Adult Medicine
General Payments · PY2025
$305.06
- Reported across 14 records
- CMS publication 2026-06-30
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2025 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $305.06 | 14 |
By paying entity
PY2025 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Novo Nordisk AS | $69.90 | 3 |
| PFIZER INC. | $41.89 | 2 |
| ABBVIE INC. | $32.09 | 1 |
| Acerta Pharma LLC | $31.61 | 2 |
| GlaxoSmithKline, LLC. | $30.12 | 1 |
| Phathom Pharmaceuticals, Inc. | $25.43 | 1 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $21.34 | 1 |
| Exact Sciences Corporation | $20.15 | 1 |
| Amgen Inc. | $16.56 | 1 |
| Lilly USA, LLC | $15.97 | 1 |
By program year
All program years on this page · sorted by year
| Program year | Amount | Records |
|---|---|---|
| PY2025 | $305.06 | 14 |
Payment records · PY2025 (14)
Ordering applied by this site (paying entity, then date) · record values are shown as CMS published them
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $32.09 | 04/01/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1204498571 | CMS |
| Amgen Inc. | $16.56 | 09/12/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1228380818 | CMS |
| AstraZeneca Pharmaceuticals LP | $13.55 | 04/15/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1207278173 | CMS |
| AstraZeneca Pharmaceuticals LP | $18.06 | 05/20/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1207073841 | CMS |
| Exact Sciences Corporation | $20.15 | 06/11/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1235415759 | CMS |
| GlaxoSmithKline, LLC. | $30.12 | 05/29/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1191475003 | CMS |
| Lilly USA, LLC | $15.97 | 05/20/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1186784359 | CMS |
| Novartis Pharmaceuticals Corporation | $21.34 | 05/15/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1200594506 | CMS |
| Novo Nordisk Inc | $22.99 | 04/08/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1188530996 | CMS |
| Novo Nordisk Inc | $22.58 | 08/08/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1188209344 | CMS |
| Novo Nordisk Inc | $24.33 | 09/16/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1188962199 | CMS |
| PFIZER INC. | $21.12 | 04/07/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1231295317 | CMS |
| PFIZER INC. | $20.77 | 07/31/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1231692468 | CMS |
| Phathom Pharmaceuticals, Inc. | $25.43 | 06/30/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1219344426 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2025
- Source files
- Dataset page · Bulk file · PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.